CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 183 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2023. The put-call ratio across all filers is 0.54 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,561,047 | -48.7% | 57,179 | -46.4% | 0.42% | -46.5% |
| Q1 2024 | $4,990,601 | +33.6% | 106,614 | +1.5% | 0.78% | +17.3% |
| Q4 2023 | $3,736,078 | +33.4% | 105,005 | +11.5% | 0.66% | +22.6% |
| Q3 2023 | $2,801,181 | +47.3% | 94,189 | +40.7% | 0.54% | +73.4% |
| Q4 2021 | $1,902,000 | – | 66,948 | – | 0.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 479,681 | $21,484,912 | 8.12% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $6,315,390 | 7.68% |
| STEMPOINT CAPITAL LP | 551,095 | $24,683,545 | 7.25% |
| EcoR1 Capital, LLC | 4,155,375 | $186,119,246 | 5.69% |
| ACUTA CAPITAL PARTNERS, LLC | 135,141 | $6,052,965 | 5.10% |
| First Light Asset Management, LLC | 1,200,508 | $53,770,753 | 4.71% |
| Ikarian Capital, LLC | 588,818 | $26,373,158 | 4.59% |
| Paradigm Biocapital Advisors LP | 2,513,302 | $112,570,797 | 4.31% |
| MPM BioImpact LLC | 557,184 | $24,956,271 | 3.88% |
| Cormorant Asset Management, LP | 1,350,000 | $60,466,500 | 3.49% |